16-Week Data From SALWEEN Fill the Gap for Patients With PCV - Summary - MDSpire

16-Week Data From SALWEEN Fill the Gap for Patients With PCV

Discover insights from Professor Gemmy Cheung as she discusses the promising first-time data from the SALWEEN study on the use of faricimab in patients with polypoidal choroidal vasculopathy (PCV).

  • By

  • Gemmy Cheung, MBBS, FRCOphth, FAMS, MCI

  • Michael A. Singer, MD

  • March 1, 2025

  • 9 min

Share

Objective:

To evaluate the efficacy and safety of faricimab in patients with polypoidal choroidal vasculopathy (PCV).

Key Findings:
  • Add brief definitions for BCVA and CST.
Interpretation:

Emphasize the clinical significance of the results.

Limitations:
  • Specify how the small sample size affects the findings.
Conclusion:

Highlight the importance of ongoing research.

Original Source(s)

16-Week Data From SALWEEN Fill the Gap for Patients With PCV

  • by Gemmy Cheung, MBBS, FRCOphth, FAMS, MCI, Michael A. Singer, MD

  • March 1, 2025

Related Content

Lutein Supplementation May Improve Outcomes in Early AMD

Meta-analysis found statistically significant improvements, with clearest benefits in early-stage disease

Artificial intelligence framework for multi-pathology risk assessment from retinal fundus images: deep learning approach to 15-disease screening

The Good News About AMD Prevention and Early Intervention

AMD severity is measured on a spectrum, and the sooner doctors, patients, and caregivers are aware of its presence, the sooner everyone can work together to protect against it.